Ionis Pharmaceuticals Inc
SWB:ISI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Ionis Pharmaceuticals Inc
SWB:ISI
|
US |
|
C
|
Caseys General Stores Inc
SWB:CS2
|
US |
|
S
|
Standard Chartered PLC
OTC:SCBFY
|
UK |
Intrinsic Value
The intrinsic value of 
Ionis Pharmaceuticals Inc (ISI) under the Base Case is 25.88 EUR per share.
Compared with the current market price of 39.09 EUR, the stock appears
Overvalued by 34% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Ionis Pharmaceuticals Does
Ionis Pharmaceuticals is a drug company that makes medicines based on antisense technology, a way to turn off harmful proteins by targeting RNA before they are made. It spends most of its effort on discovering and developing treatments for serious diseases, especially rare genetic, neurological, cardiovascular, and metabolic conditions. Its pipeline is the main business asset: it creates drug candidates and then tests them through clinical development.
- Headquarters
- United States of America US
- Employees
- 1 402
- IPO date
- May 17, 1991
Ionis Pharmaceuticals has a narrow economic moat
Patents on Ionis’s medicines and the chemical designs behind them make it harder for rivals to copy some of its treatments. But other companies can compete with different medicines, so this protection is limited to particular products and designs.
Read the full moat analysis
Revenue & Expenses Breakdown
Ionis Pharmaceuticals Inc
Earnings Waterfall
Ionis Pharmaceuticals Inc
The intrinsic value for Ionis Pharmaceuticals Inc (ISI) under the Base Case is 25.88 EUR.
Compared with the current market price of 39.09 EUR, the stock appears Overvalued by 34% .